Filspari (Sparsentan) Patent Expiration, LOE Window & CMS Spending
Filspari (Sparsentan) by Travere Therapeutics: FDA Orange Book LOE 2037-10-13, 0 AB generics, $40.6M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Travere Therapeutics |
| FDA Application & Pathway | N216403 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2037-10-13 |
| Orange Book Patents (*PED Extensions) | 3 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $40.6M |
| 2024 Medicare Part D Spend | $24.3M |
| 2024 Medicaid Spend | $16.3M |
| Reported Wholesale Price Change (CA SB 17) | 6 WAC filings (max 33.0% 2-yr change) |